Isomorphic Labs has raised $5 billion in a Series C funding round co-led by Greenoaks and Sequoia Capital, giving the artificial intelligence drug-discovery company substantial new capital to expand its research and development work.
The funding will be directed towards improving the company’s IsoDDE drug design engine, widening its pipeline of therapeutic candidates and developing global infrastructure for AI-led bioengineering. Isomorphic Labs said the investment will also support translational and clinical development systems designed to move its drug candidates towards clinical trials.
“Our drug design engine is generating molecules with precision and speed,” said Sir Demis Hassabis, Founder and CEO of Isomorphic Labs.
Capital aimed at clinical development
Isomorphic Labs said the round will help it take its first therapeutic programmes closer to clinical trials. The company’s work focuses on applying deep learning systems to biological and drug-design problems, with the stated goal of predicting biological behaviour and mapping the steps involved in developing new medicines.
The company is also using the new capital to mature IsoDDE and study more complex biological systems through advanced models. Its teams bring together machine-learning specialists and experienced drug researchers, an interdisciplinary structure aimed at translating computational discoveries into potential treatments.
- Funding: $5 billion Series C
- Lead investors: Greenoaks and Sequoia Capital
- Primary uses: IsoDDE development, therapeutic candidates and AI-led bioengineering infrastructure
- Development target: Progressing the company’s first therapeutic programmes towards clinical trials
AI moves deeper into pharmaceutical research
Neil Mehta, Founder and Managing Partner of Greenoaks, described medicine discovery as a large-scale optimisation problem and said Isomorphic Labs is positioned to apply deep-learning systems to it. Max Jaderberg, President of Isomorphic Labs, said the company was making repeatable scientific advances through its models and that these were improving the profiles of molecules under development.
The announcement reflects a growing effort to use AI beyond general-purpose software and into research-heavy industries such as pharmaceuticals and biotechnology. In this model, computational systems are used to examine biological relationships and design candidate molecules before they enter the conventional stages of laboratory and clinical development.
For technology readers in India, the round is significant as an example of how large private investments are being channelled into AI applications that depend on specialised scientific data, computing and domain expertise. However, the funding announcement does not state that Isomorphic Labs is launching a product, clinical programme or operation in India. It concerns the company’s global research and development infrastructure and its efforts to advance therapeutic candidates towards clinical trials.
Isomorphic Labs has not said that the funding makes any medicine immediately available to patients. Drug candidates still need to progress through development and clinical testing before their safety and effectiveness can be assessed.